426 related articles for article (PubMed ID: 30481785)
21. The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival.
Rae S; Spillane C; Blackshields G; Madden SF; Keenan J; Stordal B
Hum Cell; 2022 Sep; 35(5):1547-1559. PubMed ID: 35794446
[TBL] [Abstract][Full Text] [Related]
22. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
23. ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH.
Zheng G; Peng C; Jia X; Gu Y; Zhang Z; Deng Y; Wang C; Li N; Yin J; Liu X; Lu M; Tang H; He Z
Mol Cancer; 2015 Apr; 14():84. PubMed ID: 25890268
[TBL] [Abstract][Full Text] [Related]
24. miR-340 alleviates chemoresistance of osteosarcoma cells by targeting ZEB1.
Yan H; Zhang B; Fang C; Chen L
Anticancer Drugs; 2018 Jun; 29(5):440-448. PubMed ID: 29494357
[TBL] [Abstract][Full Text] [Related]
25. Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1.
Wang D; Qian G; Wang J; Wang T; Zhang L; Yang P; Lin F
Cancer Biol Ther; 2019; 20(7):999-1006. PubMed ID: 30975015
[TBL] [Abstract][Full Text] [Related]
26. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
27. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
28. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
29. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
30. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.
Li E; Hu Z; Sun Y; Zhou Q; Yang B; Zhang Z; Cao W
Tumour Biol; 2016 Jun; 37(6):7843-52. PubMed ID: 26695152
[TBL] [Abstract][Full Text] [Related]
31. Knockdown of ubiquitin‑specific protease 51 attenuates cisplatin resistance in lung cancer through ubiquitination of zinc‑finger E‑box binding homeobox 1.
Zhou F; Du C; Xu D; Lu J; Zhou L; Wu C; Wu B; Huang J
Mol Med Rep; 2020 Aug; 22(2):1382-1390. PubMed ID: 32468048
[TBL] [Abstract][Full Text] [Related]
32. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
33. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
34. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
[TBL] [Abstract][Full Text] [Related]
35. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
[TBL] [Abstract][Full Text] [Related]
37. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
38. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.
Simonin K; Brotin E; Dufort S; Dutoit S; Goux D; N'diaye M; Denoyelle C; Gauduchon P; Poulain L
Mol Cancer Ther; 2009 Nov; 8(11):3162-70. PubMed ID: 19887550
[TBL] [Abstract][Full Text] [Related]
39. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells.
Zhang P; Liu H; Xia F; Zhang QW; Zhang YY; Zhao Q; Chao ZH; Jiang ZW; Jiang CC
Int J Mol Med; 2014 Jan; 33(1):151-9. PubMed ID: 24173500
[TBL] [Abstract][Full Text] [Related]
40. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.
Gong S; Chen Y; Meng F; Zhang Y; Li C; Zhang G; Huan W; Wu F
Cell Prolif; 2018 Oct; 51(5):e12474. PubMed ID: 30069985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
